Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cost-Benefit Analysis | 46 | 2024 | 5532 | 3.320 |
Why?
|
Quality-Adjusted Life Years | 24 | 2023 | 1734 | 2.410 |
Why?
|
Models, Economic | 10 | 2020 | 717 | 1.950 |
Why?
|
Carotid Stenosis | 10 | 2020 | 864 | 1.730 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2021 | 3253 | 1.410 |
Why?
|
Health Care Costs | 8 | 2022 | 3265 | 1.240 |
Why?
|
Cardiovascular Diseases | 21 | 2023 | 15638 | 1.100 |
Why?
|
Reimbursement, Incentive | 2 | 2020 | 548 | 0.910 |
Why?
|
Budgets | 2 | 2022 | 232 | 0.840 |
Why?
|
Judgment | 1 | 2023 | 273 | 0.730 |
Why?
|
Stroke | 15 | 2024 | 9791 | 0.680 |
Why?
|
Fibrinolytic Agents | 2 | 2020 | 2082 | 0.640 |
Why?
|
Physician Incentive Plans | 1 | 2020 | 164 | 0.630 |
Why?
|
Life Expectancy | 6 | 2023 | 1249 | 0.620 |
Why?
|
Anemia, Sickle Cell | 2 | 2024 | 1065 | 0.590 |
Why?
|
Plaque, Atherosclerotic | 6 | 2020 | 1547 | 0.580 |
Why?
|
Ultrasonography, Doppler | 1 | 2019 | 463 | 0.570 |
Why?
|
Brain Ischemia | 6 | 2022 | 3038 | 0.550 |
Why?
|
Epidemics | 5 | 2021 | 517 | 0.500 |
Why?
|
Drug Costs | 4 | 2022 | 1196 | 0.500 |
Why?
|
Immunoconjugates | 1 | 2022 | 968 | 0.480 |
Why?
|
Diabetic Angiopathies | 1 | 2019 | 806 | 0.470 |
Why?
|
Periodontitis | 1 | 2019 | 578 | 0.470 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2020 | 645 | 0.460 |
Why?
|
Quality Indicators, Health Care | 2 | 2024 | 1813 | 0.460 |
Why?
|
Hyperlipidemias | 1 | 2018 | 773 | 0.430 |
Why?
|
Primary Prevention | 3 | 2018 | 1189 | 0.430 |
Why?
|
Cholesterol, LDL | 2 | 2021 | 2396 | 0.410 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1427 | 0.410 |
Why?
|
Cardiology | 1 | 2023 | 1701 | 0.400 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2145 | 0.400 |
Why?
|
Thrombolytic Therapy | 2 | 2020 | 2058 | 0.390 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7451 | 0.380 |
Why?
|
Vascular Diseases | 1 | 2019 | 1162 | 0.370 |
Why?
|
Tissue Plasminogen Activator | 1 | 2017 | 1166 | 0.370 |
Why?
|
Nutrition Surveys | 5 | 2019 | 1734 | 0.370 |
Why?
|
United States | 29 | 2024 | 73121 | 0.350 |
Why?
|
Finger Injuries | 1 | 2011 | 145 | 0.340 |
Why?
|
Humans | 86 | 2024 | 768451 | 0.330 |
Why?
|
Atherosclerosis | 2 | 2015 | 3431 | 0.330 |
Why?
|
Nails | 1 | 2011 | 298 | 0.320 |
Why?
|
Risk Assessment | 11 | 2019 | 24311 | 0.320 |
Why?
|
Coronary Vessels | 1 | 2020 | 3122 | 0.320 |
Why?
|
Computer Simulation | 8 | 2022 | 6278 | 0.310 |
Why?
|
Preventive Medicine | 2 | 2020 | 245 | 0.310 |
Why?
|
Motivation | 1 | 2018 | 2034 | 0.310 |
Why?
|
Decision Support Systems, Clinical | 1 | 2017 | 1176 | 0.290 |
Why?
|
Thrombectomy | 3 | 2022 | 706 | 0.290 |
Why?
|
Models, Neurological | 1 | 2016 | 1784 | 0.290 |
Why?
|
Laboratories | 1 | 2011 | 463 | 0.290 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2023 | 12242 | 0.280 |
Why?
|
Quality Improvement | 2 | 2020 | 3858 | 0.280 |
Why?
|
Coronary Artery Disease | 3 | 2022 | 6551 | 0.280 |
Why?
|
Calcium | 1 | 2020 | 5793 | 0.280 |
Why?
|
Psychotic Disorders | 1 | 2022 | 3278 | 0.270 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2591 | 0.270 |
Why?
|
Cities | 7 | 2022 | 546 | 0.260 |
Why?
|
Mass Screening | 4 | 2015 | 5455 | 0.260 |
Why?
|
Ischemic Attack, Transient | 3 | 2024 | 878 | 0.250 |
Why?
|
Asymptomatic Diseases | 3 | 2019 | 591 | 0.250 |
Why?
|
Aged | 29 | 2021 | 171520 | 0.250 |
Why?
|
Middle Aged | 35 | 2021 | 223418 | 0.240 |
Why?
|
Drug Combinations | 2 | 2023 | 2079 | 0.240 |
Why?
|
Aged, 80 and over | 15 | 2021 | 59680 | 0.240 |
Why?
|
HIV Infections | 8 | 2023 | 17564 | 0.230 |
Why?
|
Cerebrovascular Circulation | 1 | 2014 | 2737 | 0.230 |
Why?
|
Markov Chains | 5 | 2017 | 977 | 0.220 |
Why?
|
Fluorides | 1 | 2024 | 134 | 0.210 |
Why?
|
Burns | 2 | 2012 | 1887 | 0.210 |
Why?
|
Male | 37 | 2024 | 364781 | 0.210 |
Why?
|
Heart Failure | 3 | 2023 | 11857 | 0.210 |
Why?
|
Chest Pain | 2 | 2020 | 1099 | 0.210 |
Why?
|
Delivery of Health Care | 2 | 2018 | 5367 | 0.200 |
Why?
|
Surgical Flaps | 1 | 2011 | 1683 | 0.200 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2024 | 147 | 0.200 |
Why?
|
Gross Domestic Product | 1 | 2022 | 77 | 0.190 |
Why?
|
Primary Health Care | 1 | 2018 | 4737 | 0.190 |
Why?
|
Models, Theoretical | 3 | 2020 | 3590 | 0.190 |
Why?
|
Female | 38 | 2024 | 396943 | 0.190 |
Why?
|
Decision Support Techniques | 3 | 2024 | 2010 | 0.190 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3543 | 0.180 |
Why?
|
Itraconazole | 2 | 2012 | 43 | 0.180 |
Why?
|
Antibodies, Bispecific | 1 | 2023 | 204 | 0.180 |
Why?
|
Coronary Angiography | 3 | 2022 | 4526 | 0.180 |
Why?
|
Quality of Life | 4 | 2020 | 13497 | 0.170 |
Why?
|
Fluconazole | 2 | 2012 | 156 | 0.170 |
Why?
|
Decision Making, Organizational | 1 | 2020 | 136 | 0.170 |
Why?
|
Hemophilia A | 1 | 2023 | 359 | 0.170 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2023 | 1244 | 0.170 |
Why?
|
Immunization, Secondary | 1 | 2021 | 371 | 0.160 |
Why?
|
American Heart Association | 1 | 2023 | 1049 | 0.160 |
Why?
|
Policy | 1 | 2022 | 515 | 0.150 |
Why?
|
Adult | 24 | 2023 | 223542 | 0.150 |
Why?
|
Cost Savings | 4 | 2019 | 916 | 0.150 |
Why?
|
Sodium | 1 | 2023 | 1595 | 0.150 |
Why?
|
Mycoses | 2 | 2012 | 386 | 0.140 |
Why?
|
Tetrazoles | 1 | 2023 | 922 | 0.140 |
Why?
|
Algorithms | 5 | 2024 | 14158 | 0.140 |
Why?
|
Heptanoic Acids | 2 | 2009 | 344 | 0.140 |
Why?
|
Myocardial Perfusion Imaging | 2 | 2020 | 672 | 0.140 |
Why?
|
Decision Making | 4 | 2023 | 3961 | 0.140 |
Why?
|
Comparative Effectiveness Research | 2 | 2019 | 712 | 0.140 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 1066 | 0.130 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1518 | 0.130 |
Why?
|
Urban Population | 2 | 2021 | 2047 | 0.130 |
Why?
|
Cholesterol | 3 | 2016 | 2910 | 0.130 |
Why?
|
Substance Abuse, Intravenous | 1 | 2020 | 530 | 0.130 |
Why?
|
Risk Factors | 10 | 2020 | 74915 | 0.130 |
Why?
|
Cost of Illness | 2 | 2022 | 1960 | 0.130 |
Why?
|
Antifungal Agents | 2 | 2012 | 761 | 0.120 |
Why?
|
Amyloidosis | 1 | 2022 | 879 | 0.120 |
Why?
|
Treatment Outcome | 8 | 2022 | 65409 | 0.120 |
Why?
|
Secondary Prevention | 2 | 2019 | 1479 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2020 | 10358 | 0.110 |
Why?
|
Brain Infarction | 1 | 2016 | 290 | 0.110 |
Why?
|
Cerebral Revascularization | 1 | 2016 | 264 | 0.110 |
Why?
|
Babesia microti | 1 | 2013 | 31 | 0.110 |
Why?
|
Antihypertensive Agents | 1 | 2023 | 2028 | 0.110 |
Why?
|
Endarterectomy, Carotid | 2 | 2016 | 558 | 0.110 |
Why?
|
Time Factors | 7 | 2020 | 40271 | 0.110 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2022 | 2203 | 0.110 |
Why?
|
Babesiosis | 1 | 2013 | 92 | 0.100 |
Why?
|
Kerosene | 1 | 2012 | 15 | 0.100 |
Why?
|
Pyrroles | 2 | 2009 | 1127 | 0.100 |
Why?
|
Calibration | 4 | 2019 | 823 | 0.100 |
Why?
|
Incidence | 5 | 2022 | 21552 | 0.100 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2019 | 1092 | 0.100 |
Why?
|
Information Dissemination | 1 | 2020 | 1138 | 0.100 |
Why?
|
ROC Curve | 2 | 2017 | 3624 | 0.100 |
Why?
|
Weight Loss | 1 | 2023 | 2710 | 0.100 |
Why?
|
Probability | 1 | 2017 | 2483 | 0.100 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2022 | 3783 | 0.090 |
Why?
|
Blood Donors | 1 | 2013 | 345 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 3 | 2020 | 36840 | 0.090 |
Why?
|
Coronary Disease | 2 | 2020 | 5926 | 0.090 |
Why?
|
Glucose | 1 | 2023 | 4355 | 0.090 |
Why?
|
Data Collection | 1 | 2020 | 3329 | 0.090 |
Why?
|
Mental Health Services | 1 | 2023 | 1732 | 0.090 |
Why?
|
Population Surveillance | 3 | 2019 | 2601 | 0.090 |
Why?
|
Rural Population | 1 | 2021 | 2317 | 0.090 |
Why?
|
Cardiomyopathies | 1 | 2022 | 2056 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2022 | 7863 | 0.080 |
Why?
|
Contracture | 1 | 2012 | 236 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 1120 | 0.080 |
Why?
|
South Africa | 4 | 2016 | 1870 | 0.080 |
Why?
|
Skin Transplantation | 2 | 2012 | 1097 | 0.080 |
Why?
|
Stroke Volume | 1 | 2023 | 5620 | 0.080 |
Why?
|
Bayes Theorem | 1 | 2017 | 2358 | 0.080 |
Why?
|
Parents | 1 | 2022 | 3596 | 0.080 |
Why?
|
Dyslipidemias | 1 | 2016 | 874 | 0.080 |
Why?
|
Cerebral Angiography | 1 | 2014 | 1282 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2011 | 2040 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2022 | 15460 | 0.070 |
Why?
|
Magnetic Resonance Angiography | 1 | 2015 | 1434 | 0.070 |
Why?
|
Endovascular Procedures | 1 | 2022 | 2258 | 0.070 |
Why?
|
Models, Statistical | 6 | 2020 | 5103 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2533 | 0.070 |
Why?
|
Dementia | 1 | 2022 | 2723 | 0.070 |
Why?
|
Retrospective Studies | 6 | 2024 | 81834 | 0.070 |
Why?
|
Cause of Death | 1 | 2017 | 3727 | 0.070 |
Why?
|
Survival Analysis | 2 | 2017 | 10125 | 0.070 |
Why?
|
Drug Prescriptions | 1 | 2015 | 1677 | 0.060 |
Why?
|
Registries | 1 | 2022 | 8373 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9263 | 0.060 |
Why?
|
Hypolipidemic Agents | 1 | 2010 | 609 | 0.060 |
Why?
|
Health Policy | 1 | 2017 | 2699 | 0.060 |
Why?
|
Patient-Centered Care | 1 | 2015 | 1439 | 0.060 |
Why?
|
Anticoagulants | 1 | 2020 | 4840 | 0.060 |
Why?
|
Ultrasonography | 2 | 2014 | 5995 | 0.060 |
Why?
|
Life Style | 1 | 2016 | 3929 | 0.060 |
Why?
|
HIV | 2 | 2022 | 1596 | 0.060 |
Why?
|
Neutropenia | 1 | 2009 | 892 | 0.060 |
Why?
|
Mammography | 1 | 2015 | 2436 | 0.060 |
Why?
|
Cross-Sectional Studies | 6 | 2016 | 26351 | 0.060 |
Why?
|
Health Surveys | 1 | 2013 | 4056 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5510 | 0.050 |
Why?
|
Risk | 1 | 2015 | 9642 | 0.050 |
Why?
|
Software | 1 | 2017 | 4463 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 89 | 0.050 |
Why?
|
Smoking | 2 | 2016 | 9099 | 0.050 |
Why?
|
Technetium | 1 | 2022 | 326 | 0.050 |
Why?
|
Economics | 1 | 2023 | 141 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2015 | 3629 | 0.050 |
Why?
|
Child | 4 | 2024 | 80863 | 0.050 |
Why?
|
Anticholesteremic Agents | 1 | 2008 | 972 | 0.050 |
Why?
|
Factor VIII | 1 | 2023 | 349 | 0.050 |
Why?
|
Age Distribution | 2 | 2020 | 2881 | 0.050 |
Why?
|
Prealbumin | 1 | 2022 | 259 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3230 | 0.040 |
Why?
|
Europe | 2 | 2022 | 3439 | 0.040 |
Why?
|
Adolescent | 8 | 2024 | 89168 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2024 | 2768 | 0.040 |
Why?
|
Health Status Disparities | 2 | 2021 | 1876 | 0.040 |
Why?
|
New York City | 1 | 2021 | 738 | 0.040 |
Why?
|
Atenolol | 1 | 2019 | 99 | 0.040 |
Why?
|
Drug Users | 1 | 2020 | 134 | 0.040 |
Why?
|
Cohort Studies | 5 | 2024 | 41797 | 0.040 |
Why?
|
Ramipril | 1 | 2019 | 102 | 0.040 |
Why?
|
Young Adult | 7 | 2021 | 60045 | 0.040 |
Why?
|
Disease Progression | 1 | 2015 | 13655 | 0.040 |
Why?
|
Sexuality | 1 | 2019 | 180 | 0.040 |
Why?
|
Selection Bias | 1 | 2019 | 360 | 0.040 |
Why?
|
Developing Countries | 3 | 2015 | 2901 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2023 | 1670 | 0.040 |
Why?
|
India | 2 | 2016 | 2323 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2020 | 338 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5887 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2024 | 1308 | 0.030 |
Why?
|
Insurance Claim Review | 1 | 2021 | 745 | 0.030 |
Why?
|
Carotid Arteries | 1 | 2020 | 943 | 0.030 |
Why?
|
Opiate Substitution Treatment | 1 | 2020 | 446 | 0.030 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2020 | 347 | 0.030 |
Why?
|
South America | 1 | 2016 | 180 | 0.030 |
Why?
|
Hypertension | 1 | 2016 | 8611 | 0.030 |
Why?
|
Medication Adherence | 2 | 2019 | 2190 | 0.030 |
Why?
|
Uncertainty | 1 | 2020 | 758 | 0.030 |
Why?
|
Blood Pressure | 1 | 2011 | 8538 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2023 | 1345 | 0.030 |
Why?
|
Angiography | 1 | 2020 | 1598 | 0.030 |
Why?
|
Pakistan | 1 | 2016 | 298 | 0.030 |
Why?
|
Guatemala | 1 | 2015 | 161 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2022 | 1076 | 0.030 |
Why?
|
Renin-Angiotensin System | 1 | 2019 | 735 | 0.030 |
Why?
|
Erythrocytes | 1 | 2024 | 2422 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2017 | 993 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10647 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2019 | 2596 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9505 | 0.030 |
Why?
|
Policy Making | 1 | 2017 | 545 | 0.030 |
Why?
|
Infant | 3 | 2024 | 36497 | 0.030 |
Why?
|
Kenya | 1 | 2016 | 757 | 0.030 |
Why?
|
Mexico | 1 | 2015 | 766 | 0.030 |
Why?
|
Endemic Diseases | 1 | 2013 | 191 | 0.030 |
Why?
|
Child, Preschool | 3 | 2024 | 42623 | 0.030 |
Why?
|
Yoga | 1 | 2016 | 281 | 0.020 |
Why?
|
Burns, Chemical | 1 | 2012 | 124 | 0.020 |
Why?
|
Hemorrhage | 1 | 2023 | 3458 | 0.020 |
Why?
|
Patient Transfer | 1 | 2018 | 796 | 0.020 |
Why?
|
China | 1 | 2016 | 2398 | 0.020 |
Why?
|
Economics, Pharmaceutical | 1 | 2010 | 88 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2016 | 1820 | 0.020 |
Why?
|
Neck | 1 | 2014 | 736 | 0.020 |
Why?
|
Life Tables | 1 | 2009 | 368 | 0.020 |
Why?
|
Diet, Mediterranean | 1 | 2016 | 747 | 0.020 |
Why?
|
Necrosis | 1 | 2013 | 1621 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2020 | 2823 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20231 | 0.020 |
Why?
|
Models, Econometric | 1 | 2009 | 215 | 0.020 |
Why?
|
Injury Severity Score | 1 | 2012 | 1053 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2917 | 0.020 |
Why?
|
Carotid Artery Diseases | 1 | 2014 | 879 | 0.020 |
Why?
|
Disease Transmission, Infectious | 1 | 2013 | 562 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3471 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3708 | 0.020 |
Why?
|
Aspirin | 1 | 2019 | 3139 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 21156 | 0.020 |
Why?
|
Forecasting | 1 | 2016 | 2950 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2009 | 10784 | 0.020 |
Why?
|
Public Health | 1 | 2020 | 2693 | 0.020 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2010 | 387 | 0.020 |
Why?
|
Needs Assessment | 1 | 2012 | 1146 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10601 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3412 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2012 | 1839 | 0.010 |
Why?
|
Hospitals | 1 | 2018 | 3906 | 0.010 |
Why?
|
Regression Analysis | 1 | 2014 | 6353 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2016 | 2079 | 0.010 |
Why?
|
Patient Selection | 1 | 2016 | 4266 | 0.010 |
Why?
|
Canada | 1 | 2009 | 2143 | 0.010 |
Why?
|
Health Services Research | 1 | 2011 | 1815 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 6217 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2024 | 26395 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8051 | 0.010 |
Why?
|
Prevalence | 1 | 2020 | 15880 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2012 | 4834 | 0.010 |
Why?
|
Lipids | 1 | 2013 | 3346 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2013 | 39430 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20762 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8753 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2016 | 4538 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14728 | 0.010 |
Why?
|
Exercise | 1 | 2016 | 5940 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 3042 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18478 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12561 | 0.010 |
Why?
|
Body Mass Index | 1 | 2016 | 13030 | 0.010 |
Why?
|
Diet | 1 | 2016 | 8098 | 0.010 |
Why?
|
Papillomavirus Infections | 1 | 2010 | 1638 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 9066 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 30028 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2010 | 11249 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2011 | 14766 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15965 | 0.010 |
Why?
|
Prospective Studies | 1 | 2014 | 54914 | 0.010 |
Why?
|